BVXV

BiondVax Pharmaceuticals Ltd. Rebrands as Scinai Immunotherapeutics Ltd. to Reflect New Focus on Development of Novel Inflammation and Immunology (I&I) Biological Therapeutics

Retrieved on: 
Wednesday, September 6, 2023
GMP, Inhalation, Asthma, IPO, Drug development, Failure, Half-life, University Medical Center, COVID-19, BVXV, WLA, Psoriasis, Science, HS, VHH, Hidradenitis suppurativa, CDMO, Max Planck Institute for Multidisciplinary Sciences, CGMP, Risk, UMG, CUSIP, Hook effect, Max Planck Society, IBN, Safety, Fine chemical, Vaccine, Pharmaceutical industry, Medicine

In the past two years, the Company has substantially revamped its senior management team and pharmaceuticals development programs and recently announced its expansion into the CDMO business under the banner Scinai Bioservices.

Key Points: 
  • In the past two years, the Company has substantially revamped its senior management team and pharmaceuticals development programs and recently announced its expansion into the CDMO business under the banner Scinai Bioservices.
  • NanoAbs are alpaca-derived recombinant variable domain of heavy-chain-only antibodies and are also known as nanobodies or VHH antibodies.
  • This process can often take many years, cost hundreds of millions of dollars, yet nevertheless incurs a high rate of failure.
  • We have a sharp commercial focus and a pipeline with blockbuster potential, steeped in science, strong leadership and an expertly designed technological base.

BiondVax Reports Second Quarter Financial Results and Provides Business Update

Retrieved on: 
Friday, August 11, 2023
GMP, Partnership, Asthma, Drug development, Table, Agility, University Medical Center, COVID-19, BVXV, Securities and Exchange Commission of Pakistan, Psoriasis, Public expenditure, VHH, CDMO, Animal, Laboratory, Max Planck, Security (finance), BiondVax, IBN, Pharmaceutical industry, Cryptocurrency

BiondVax’s unaudited financial results will be submitted to the Securities and Exchange Commission on Form 6‑K.

Key Points: 
  • BiondVax’s unaudited financial results will be submitted to the Securities and Exchange Commission on Form 6‑K.
  • As announced previously, BiondVax has decided to leverage its aseptic manufacturing site and laboratories by creating a CDMO business unit in parallel to its innovative R&D business unit.
  • BiondVax is pursuing a strategic partnership for its COVID-19 self-administered inhaled NanoAb therapeutic/prophylactic which demonstrated highly promising in vivo results in animals.
  • BiondVax holds exclusive options for exclusive licenses at pre agreed financial terms for each of the resulting NanoAbs.

Nasdaq Grants BiondVax Extension to Regain Compliance with Listing Rules

Retrieved on: 
Tuesday, August 1, 2023
Reichmann, Partnership, COVID-19, BVXV, Psoriasis, CDMO, Annual report, BiondVax, IBN, Pharmaceutical industry

JERUSALEM, Aug. 01, 2023 (GLOBE NEWSWIRE) -- via IBN -- BiondVax Pharmaceuticals Ltd. (Nasdaq: BVXV), a biotechnology company focused on developing, manufacturing, and commercializing innovative immunotherapeutic products primarily for the treatment of infectious and autoimmune diseases, today announced that Nasdaq reviewed BiondVax’s multi-faceted plan to regain compliance with Nasdaq’s Listing Rule 5550(b) and provided it an extension until October 30, 2023, to demonstrate compliance.

Key Points: 
  • JERUSALEM, Aug. 01, 2023 (GLOBE NEWSWIRE) -- via IBN -- BiondVax Pharmaceuticals Ltd. (Nasdaq: BVXV), a biotechnology company focused on developing, manufacturing, and commercializing innovative immunotherapeutic products primarily for the treatment of infectious and autoimmune diseases, today announced that Nasdaq reviewed BiondVax’s multi-faceted plan to regain compliance with Nasdaq’s Listing Rule 5550(b) and provided it an extension until October 30, 2023, to demonstrate compliance.
  • As previously disclosed, BiondVax received a deficiency letter dated May 1, 2023, from Nasdaq notifying the Company that it is not in compliance with the minimum stockholders’ equity requirement for continued listing on the Nasdaq Capital Market.
  • “We are very pleased that Nasdaq has reviewed our plan and provided us the time to proceed with various initiatives already underway that alone or together will allow us to regain compliance with the shareholders’ equity listing requirement,” said Mr. Amir Reichman, BiondVax’s CEO.
  • Based on BiondVax’s plans, Nasdaq has provided an extension of time until October 30, 2023, for the company to demonstrate it has regained compliance.

IBN Announces Latest Episode of The Bell2Bell Podcast featuring Amir Reichman, CEO of BiondVax Pharmaceuticals Ltd.

Retrieved on: 
Tuesday, July 11, 2023
Reichmann, Infection, Asthma, Series, Interview, Macular degeneration, COVID-19, BVXV, Inflammation, Psoriasis, Patient, Autoimmune disease, Steroid, Podcast, Single-domain antibody, Interleukin, Letter, Max Planck Society, Humanitarian use licenses, IBN, Conditional sentence, Pharmaceutical industry

The Bell2Bell Podcast delivers informative updates and exclusive interviews with executives operating in fast-moving industries.

Key Points: 
  • The Bell2Bell Podcast delivers informative updates and exclusive interviews with executives operating in fast-moving industries.
  • Bell2Bell’s latest podcast features Amir Reichman, CEO of BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV) .
  • To begin the latest interview, Reichman discussed the company’s recent achievements, as detailed in a letter to shareholders issued late last year.
  • The latest installment of The Bell2Bell Podcast continues to reinforce IBN’s commitment to the expansion of its robust network of brands, client partners, followers, and the growing IBN Podcast Series .

BiondVax signs exclusive license agreement for development and commercialization of a novel anti-IL-17 antibody for treatment of autoimmune and inflammatory diseases including psoriasis

Retrieved on: 
Monday, June 5, 2023
National Psoriasis Foundation, Psoriatic arthritis, Disease, Human, Asthma, Therapy, Macular degeneration, IBD, University Medical Center, Hook effect, Inflammation, Max Planck Society, COVID-19, Psoriasis, Interleukin 17, BVXV, COVID, Max Planck Institute for Multidisciplinary Sciences, IL-17A, Light, VHH, Patient, Patent, Hidradenitis suppurativa, MPG, UMG, Mab, Max Planck, Knowledge, Cytokine, Transport, BiondVax, Skin, Autoimmunity, Pharmaceutical industry, Vaccine

Psoriasis affects over 3% of U.S. population, with global biologics treatment market over $9B annually and growing with 7% CAGR.

Key Points: 
  • Psoriasis affects over 3% of U.S. population, with global biologics treatment market over $9B annually and growing with 7% CAGR.
  • Excess presence of IL‑17 is implicated in a wide range of autoimmune and inflammatory diseases including psoriasis, and therefore is the molecular target for several commercially available therapeutics.
  • Of the biological treatments, monoclonal antibodies (mAbs) targeting IL-17A were the first mAbs to be approved for treatment of plaque psoriasis.
  • BiondVax is working on plans to develop the drug also as a subcutaneous injection for systemic treatment targeting patients with moderate to severe plaque psoriasis.

BiondVax Files FY 2022 Financial Statements and Annual Report on Form 10-K and Provides Business Update

Retrieved on: 
Monday, April 17, 2023
Exercise, SAB, Human, Drug development, Table, University Medical Center, Hook effect, Max Planck Society, COVID-19, CGMP, BVXV, GAAP, Associate, Psoriasis, VHH, CDMO, Patient, Organic compound, Annual report, Risk, Laboratory, Max Planck Institute for Multidisciplinary Sciences, MPG, IL-17, UMG, Immune system, Growth, Security (finance), Cytokine, EIB, BiondVax, Caregiver, Global Research Collaboration for Infectious Disease Preparedness, Cryptocurrency, Vaccine, Fine chemical, Pharmaceutical industry, VOC

At the same time, the Company filed its Annual Report on Form 10-K with the Securities and Exchange Commission.

Key Points: 
  • At the same time, the Company filed its Annual Report on Form 10-K with the Securities and Exchange Commission.
  • In addition, having access to a multi-asset pipeline would hedge BiondVax’s risk and provide greater opportunity and flexibility in pursuing partnering deals with other pharma companies.
  • As of December 31, 2022, BiondVax had cash and cash equivalents of $14 million as compared to $17.3 million as of December 31, 2021.
  • The complete audited financial results are available in the Company’s Annual Report on Form 10-K for the year ended December 31, 2022, filed with the Securities and Exchange Commission.

BiondVax to Present at BIO-Europe Spring

Retrieved on: 
Thursday, March 16, 2023
BVXV, Communication, Psoriatic arthritis, Psoriasis, BiondVax, COVID-19, Asthma, Macular degeneration, Hook effect, Pharmaceutical industry

JERUSALEM, March 16, 2023 (GLOBE NEWSWIRE) -- via InvestorWire – BiondVax Pharmaceuticals Ltd .

Key Points: 
  • JERUSALEM, March 16, 2023 (GLOBE NEWSWIRE) -- via InvestorWire – BiondVax Pharmaceuticals Ltd .
  • The event is expected to bring together over 2,800 executives from biotech, pharma and finance companies to engage in 15,000+ one-to-one meetings.
  • Reichman and Joshua Phillipson, Director of Investor Relations and Communications, will be available to meet potential partners, collaborators, and investors.
  • To schedule a meeting with BiondVax register now at https://informaconnect.com/bioeurope-spring/ .

IBN Announces ‘Test. Optimize. Scale.’ Interview with BiondVax Pharmaceuticals Ltd. CEO Amir Reichman Discussing De-Risked Development Pipeline and Strategic Partnerships with Premier European Research Institutes

Retrieved on: 
Friday, March 3, 2023
Research, Patent, MBA, Pharmacology, Michael J. Freeman, IBN, Max Planck Society, Vaccine, IP, Mitsubishi Tanabe Pharma, BiondVax, The Michael J. Fox Foundation, Running, Humanitarian use licenses, III, Engineering, BVXV, Diagnosis, Biotechnology, Skin, Reichmann, Entrepreneurship, Interview, Pharmaceutical industry, Test

Scale., a podcast series featuring industry leaders and pioneers sharing insights and experiences of growing their businesses to scale.

Key Points: 
  • Scale., a podcast series featuring industry leaders and pioneers sharing insights and experiences of growing their businesses to scale.
  • The broadcast, hosted by Jason Fishman, SVP Digital Strategy for Digital Niche Agency , is available for on-demand listening on Test.
  • To begin the interview, Reichman discussed his professional journey leading up to joining BiondVax in 2021.
  • That was a very nice start to my career as an entrepreneur… I didn’t stay with NeuroDerm until the exit.

BiondVax Presenting at BIO CEO & Investor Conference

Retrieved on: 
Thursday, February 2, 2023
BVXV, Biotechnology Innovation Organization, Psoriatic arthritis, COVID-19, VHH, BIO, Conference, Macular degeneration, Asthma, Psoriasis, Neutralizing antibody, Degenerative disease, Pharmaceutical industry

( Nasdaq: BVXV ), a biotechnology company focused on developing, manufacturing, and commercializing innovative immunotherapeutic products primarily for the treatment of infectious and autoimmune diseases, announced today that its CEO Amir Reichman will present at the BIO CEO & Investor Conference .

Key Points: 
  • ( Nasdaq: BVXV ), a biotechnology company focused on developing, manufacturing, and commercializing innovative immunotherapeutic products primarily for the treatment of infectious and autoimmune diseases, announced today that its CEO Amir Reichman will present at the BIO CEO & Investor Conference .
  • The conference is taking place Feb. 6-9, 2023, in New York.
  • Parties registered for the conference are encouraged to schedule one-to-one appointments via the Biotechnology Innovation Organization (BIO) partnering platform at https://www.partnering.bio.org/ceo2023 .
  • Alternatively, parties interested in meeting with Reichman and Germain may contact the Company directly at the contact information below.

BiondVax’s Innovative Inhaled Anti-SARS-CoV-2 NanoAb Virtually Prevented Illness When Administered Prophylactically in Preclinical In Vivo Study

Retrieved on: 
Monday, January 23, 2023
COVID-19, Psoriasis, BVXV, Weight loss, AMD, Infection, Psoriatic arthritis, Degenerative disease, Asthma, Pharmaceutical industry

“We continue to be thrilled with the results of this ongoing trial,” stated Amir Reichman, BiondVax’s CEO.

Key Points: 
  • “We continue to be thrilled with the results of this ongoing trial,” stated Amir Reichman, BiondVax’s CEO.
  • Our inhaled NanoAb is designed to be self-administered at the time of choosing to generate rapid protection from COVID illness.
  • Results of the dosing study will inform the design of future studies of BiondVax’s anti‑COVID‑19 inhaled NanoAb.
  • For example, as demonstrated by this preclinical study, BiondVax’s NanoAb is efficacious when administered through inhalation rather than by injection as with currently available COVID-19 mAb therapies.